Posted by Michael Wonder on 10 Jun 2025
Alnylam receives European Commission approval for Amvuttra (vutrisiran) for the treatment of ATTR amyloidosis with cardiomyopathy
9 June 2025 - Decision follows recent authorisations in the US and Brazil.
Alnylam Pharmaceuticals today announced that the European Commission has granted approval for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy.
